12-Week Clinical Study Demonstrates 30% Reduction in Senescent Cells, 5.2-Year Reversal in Skin Age, and Significant Improvement in Wrinkles and Fine Lines

PAREMINA is excited to announce the successful completion of a clinical trial conducted by Express Rx, demonstrating the powerful effects of its key ingredients, Procyanidin C1 (PCC) and Cellumiva™. The 12-week, double-blind, placebo-controlled trial involving 72 participants showed a remarkable 30% reduction in senescent cells within the dermis, resulting in a biological skin age reversal of 5.2 years. Participants also experienced significant improvements in skin texture, fine lines, and wrinkles.

Clinical assessments employed advanced techniques like SA-β-gal staining for senescent cell clearance and skin-specific methylome modelling to determine the biological age of the skin. The findings highlight the potential of PCC and Cellumiva™ as powerful agents for skin rejuvenation, furthering PAREMINA’s mission to offer science-backed beauty solutions.

For more information, visit ClinicalTrials.gov (Study ID: NCT06641869).

About PAREMINA

PAREMINA, with origins in Switzerland and a presence in the U.S., is a company specializing in anti-aging solutions. With over 60 years of research in natural antioxidants and bioactives, the company focuses on supplements that target aging at a molecular level. It contributes to the longevity and beauty movement by promoting a ‘BeautySpan’ of lifelong well-being and radiance.

About Cellumiva

Cellumiva™ is a cutting-edge senolytic complex that combines PCC1, Pterostilbene, and Spermidine to effectively reduce senescent cells in the skin, reversing biological skin aging. It is core component of PAREMINA’s flagship product NEO CELL.